



XTP1 facilitates the growth and development of gastric cancer by activating *CDK6*

Kang Li¹, Rulan Ma¹, Lei Meng¹, Qing Wang², Jun Cao¹, Dawei Yuan¹, Tuanhe Sun¹, Li Kang³, Nan Hao¹, Haonan Wang¹, Kun Zhu¹

¹Department of Surgical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China; ²Department of Surgery, University of Virginia, Charlottesville, VA, USA; ³Department of Thoracic Surgery, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China

Contributions: (I) Conception and design: K Li, H Wang, K Zhu; (II) Administrative support: K Zhu; (III) Provision of study materials or patients: K Zhu; (IV) Collection and assembly of data: K Li, H Wang, R Ma, L Meng, J Cao, Q Wang, D Yuan, T Sun, L Kang, N Hao; (V) Data analysis and interpretation: K Li, R Ma, H Wang; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

Correspondence to: Kun Zhu; Haonan Wang. Department of Surgical Oncology, the First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. Email: dr.zhkun@mail.xjtu.edu.cn; hnnwang@xjtu.edu.cn.

Background: Hepatitis B virus X protein (*XTP1*) is overexpressed in tumor tissues and regulates cancer progression. However, the molecular mechanism of *XTP1* in gastric cancer (GC) is poorly understood. Hence, we aimed to dissect the underlying role of *XTP1* in the development of GC.

Methods: Lentiviruses were constructed and transfected into GC cells to upregulate or downregulate gene expression. The expressions of proteins in GC cells or tumor tissues were assessed by quantitative reverse transcription polymerase chain reaction (RT-qPCR), Western blotting, immunohistochemistry (IHC) assay, or the Gene Expression Profiling Interactive Analysis (GEPIA) database. Cell proliferation was assessed via methylthiazolyl-diphenyl-tetrazolium bromide (MTT) assay, Celigo cell counting assay, cell cycle analysis, and colony formation assay. Cell apoptosis was assessed by flow cytometry. The apoptosis-related proteins were evaluated using the human apoptosis antibody array. GC cell migration was detected by scratch wound-healing assays and Transwell migration assays. Potential downstream molecules were identified by the human GeneChip assay combined with bioinformatics analysis.

Results: We found that *XTP1* is overexpressed in GC tissues and is positively related to its pathological grade. *XTP1* knockdown restrained the growth and migration of GC cells, while *XTP1* overexpression promoted cell proliferation and suppressed apoptosis. A mechanistic study indicated that *XTP1* knockdown inhibited cyclin-dependent kinase 6 (*CDK6*) expression and that *CDK6* might be a potential downstream molecule of *XTP1*. Further study confirmed that *CDK6* depletion also suppressed GC cell proliferation and migration and increased GC cell apoptosis. Moreover, rescue experiments verified that *CDK6* knockdown abated the promotion of *XTP1* overexpression on GC progression.

Conclusions: *XTP1* facilitated the development and progression of GC cells by activating *CDK6*. Therefore, the *XTP1*-*CDK6* axis might be a potential therapeutic target for GC.

Keywords: *XTP1*; gastric cancer (GC); *CDK6*; tumor promoter; therapeutic target

Submitted Nov 07, 2022. Accepted for publication Jan 05, 2023. Published online Jan 31, 2023.

doi: 10.21037/atm-22-5933

View this article at: <https://dx.doi.org/10.21037/atm-22-5933>

Introduction

Gastric cancer (GC) is the fifth most commonly diagnosed cancer and the fourth leading cause of cancer death globally (1). In China, nearly 460,000 new cases of GC are diagnosed annually, and more than 350,000 GC-related deaths occur each year (2). Widespread tumor migration and invasion contribute to its high mortality rate. Despite the progress in treatment strategies for GC, the efficacy of conventional therapies, including surgery, chemotherapy, and radiotherapy, is still unsatisfactory. Major advances in targeted therapy and immunotherapy have started to alter the clinical landscape of GC treatment and prognosis. Moreover, numerous stimulatory and inhibitory factors have been proven to play essential roles in the growth and metastasis of GC (3). However, it is still necessary to further investigate the underlying mechanism in the pathogenesis of GC to identify useful therapeutic targets.

Hepatitis B virus X protein (*XTP1*), also known as BRCA1/BRCA2-containing complex, subunit 3 (*BRCC3*) and DEP domain containing 1B (*DEPDC1B*), was a gene screened by suppression subtractive hybridization in our study on the transactivation of *XTP1*. *XTP1* is involved in the promotion of myoblast proliferation and the retraining of precocious myogenic differentiation in skeletal myogenesis (4). Notably, accumulating evidence has revealed the protumor effects of *XTP1* in several tumors, including breast cancer (5), non-small cell lung cancer (6), bladder cancer (7,8), prostate cancer (9), malignant melanoma (10), hepatocellular carcinoma (11), pancreatic cancer (12,13), and so on (14,15). Several signaling pathways, including nuclear factor kappa-B (*NF-κB*) signaling (8), Wingless (Wnt)/β-catenin signaling (6), protein kinase B (*Akt*)/glycogen

synthase kinase 3 beta (*GSK3β*)/Snail signaling (13), ras-related C3 botulinum toxin substrate 1 (*Rac1*)-extracellular regulated protein kinases 1/2 (*ERK1/2*) signaling (15), *Rac1*-p21 protein activated kinase 1 (*PAK1*) signaling (9), and *PAK1*-LIM domain kinase 1 (*LIMK1*)-cofilin1 signaling (12), are involved in tumorigenesis and malignant progression regulated by *XTP1*. Nevertheless, the role and intrinsic molecular mechanism of *XTP1* in gastrointestinal cancer, especially GC, have not been confirmed or clarified.

In the present study, we intended to confirm the effects of *XTP1* on GC progression and investigate the mechanisms through which *XTP1* regulates tumor development. We present the following article in accordance with the ARRIVE and MDAR reporting checklists (available at <https://atm.amegroups.com/article/view/10.21037/atm-22-5933/rc>).

Methods

Antibodies

The following antibodies were used in this study: anti-*XTP1* (Abcam, USA, ab124182, 1:1,000), anti-glyceraldehyde-3-phosphate dehydrogenase (*GAPDH*) (Bioworld, USA, AP0063, 1:3,000), anti-rabbit immunoglobulin (IgG) (Beyotime, China, A0208, 1:3,000), anti-*Ki-67* (Abcam, USA, Ab16667, 1:200), anti-rabbit IgG (Abcam, USA, ab6721, 1:400), anti-cluster of differentiation (*CD*)44 (Abcam, USA, ab157107, 1:2000), anti-cyclin-dependent kinase 6 (*CDK6*) (Abcam, USA, ab151247, 1:1,000), anti-ras homolog family member U (*RHO*) (Abcam, USA, ab80315, 1:1,000), and anti-rabbit IgG (Beyotime, China, A0208, 1:3,000).

Cell culture

Human GC cell lines (AGS, SGC-7901, BGC-823, and MGC-803) (obtained from the Cell Bank of the Chinese Academy of Sciences) were cultured in Roswell Park Memorial Institute (RPMI) 1640 (Corning, USA, 10-040-CVB) with 10% fetal bovine serum (FBS) (Invitrogen, USA, 16000-044) at 37 °C and 5% CO₂.

XTP1 expression analysis using the Gene Expression Profiling Interactive Analysis (GEPIA) database

The expression level of *XTP1* in tumor tissue and adjacent

Highlight box

Key findings

- *XTP1* can promote the development and progression of GC cells by activating *CDK6*.

What is known and what is new?

- *XTP1* is overexpressed in tumor tissues and regulates cancer progression.
- *XTP1* is highly expressed in tumor tissues of GC and related to GC growth and development via promoting the expression of *CDK6*.

What is the implication, and what should change now?

- The *XTP1-CDK6* axis may be a potential therapeutic target for GC, and it can be used in further studies on GC treatment.

normal tissue of GC was investigated using the GEPIA database (<http://gepia.cancer-pku.cn/index.html>).

Patients and pathological tissue specimens

Pathological tissue specimens for immunohistochemistry (IHC) assays were collected from GC patients who underwent surgical resection at the First Affiliated Hospital of Xi'an Jiaotong University from December 2013 to January 2017. A total of 196 GC samples (including 22 adjacent normal tissue samples) were assessed in this study. No patients received any antitumor therapy before surgical resection. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the clinical ethics committee of the First Affiliated Hospital of Xi'an Jiaotong University (No. XJTU1AF2020LSK-103). The study was a retrospective study, and written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements, so it was waived by the Ethics Committee of the First Affiliated Hospital of Xi'an Jiaotong University.

IHC assay

Tissue specimens were embedded in paraffin, sliced into serial 4-nm sections, deparaffinized, and rehydrated. The slides were incubated with primary antibodies overnight at 4 °C. Subsequently, secondary antibodies were added and incubated for 60 min at 24 °C. The slides were stained with hematoxylin (Baso, China, BA4041), dehydrated and cover-slipped. Images of the stained slides were obtained using an optical microscope. All of the stained slides were independently evaluated and scored by two pathologists, and an agreement was reached after careful discussion if discrepancies occurred.

Lentivirus construction and cell transfection

The target gene was used as a template and evaluated using design software (<http://tools.genome-engineering.org>) to find the interference target sequence. The target sequence of *XTP1* was 5'-GCTGCTAGATTGGTAACGTTT-3', and the target sequence of *CDK6* was 5'-GCCCAACCAATTGAGAAGTTT-3'. The negative control sequence was 5'-TCTCCGAACGTGTCACGT-3'. Next, lentivirus construction and cell transfection were conducted according

to a published protocol (16). The transfected cells with puromycin resistance was screened by culture medium with puromycin (Clontech, USA, 631305).

Western blotting

RIPA lysis buffer was used to lyse the cells. The lysates were washed with phosphate buffered saline (PBS) and centrifuged. A BCA Protein Assay Kit (HyClone, USA, Pierce 23225) was used to detect the abundance of the proteins. The samples were loaded onto sodium dodecyl sulfate (SDS)-polyacrylamide gel electrophoresis (PAGE) gels for electrophoresis and transferred to polyvinylidene fluoride (PVDF) membranes. Then, the antibodies were added and incubated with the membranes. An enhanced chemiluminescence (ECL)-Pus/Kit (Amersham, USA, RPN2232) was used to detect the protein bands.

Reverse transcription quantitative polymerase chain reaction (RT-qPCR) analysis

TRIzol reagent (Sigma, USA, T9424) was used to extract the total RNA from GC. The complementary DNA (cDNA) was reverse transcribed according to the manufacturer's instructions (+gDNA WIPER, Vazyme, China, R123-01). Subsequently, RT-qPCR was performed to quantify the RNA expression. [Table S1](#) shows the primer sequences used in this study. The relative gene expression levels were calculated by the $2^{-\Delta\Delta C_t}$ method.

Methylthiazolyl-diphenyl-tetrazolium bromide (MTT) assay and Celigo cell counting

The cells were seeded into 96-well plates (1,500 cells/well). Then, the MTT and Celigo cell counting assays were performed according to the published protocols (16).

Colony formation assay

The cells were seeded into six-well plates (500 cells/well). The cells were cultured for 13 days and then washed with PBS. Next, 4% paraformaldehyde (1 mL) was used to fix the cells for 30–60 min. Subsequently, Giemsa dye (500 μ L) was used to stain the cells for 10–20 min. Double-distilled water (ddH₂O) was then used to wash the cells several times and dry them at 24 °C. The cell colonies were scanned using a microscope.

Apoptosis assay

Trypsin was used to digest the cells, and the digested cells were centrifuged and fixed with 70% ethanol. The cells were then stained with annexin-V-allophycocyanin (APC). Thereafter, flow cytometry was performed to identify the apoptotic cells. An apoptosis detection kit (eBioscience, USA, 88-8007) was used in this experiment.

Human apoptosis antibody array

The human apoptosis antibody array (Abcam, USA, ab134001) was used in this study according to the manufacturer's instructions. Briefly, total proteins from the cells were extracted. Biotin-labeled anti-cytokines, horseradish peroxidase-labeled streptavidin, and chemiluminescence detection reagents were added and reacted. Then, the spots on the array were scanned, and the expression levels of the proteins related to apoptosis were analyzed quantitatively.

Cell cycle analysis

The cells were centrifuged and washed with precooled Dulbecco's phosphate buffered saline (DPBS), and then centrifuged and fixed with precooled 70% ethanol. A 40× propidium iodide (PI) solution (2 mg/mL) was used to dye the cells. Flow cytometry was performed to analyze the cell cycle.

Scratch wound-healing assay

The transfected cells were seeded in 96-well plates (50,000 cells/well). Twenty-four hours later, a 96 Wounding Replicator (VP scientific, USA, VP408FH) was used to draw the scratches across the plate. Next, 2% PBS was added to wash the cells several times. Images were scanned at 0, 24, and 48 h using the Celigo image cytometry system (Nexcelom, USA), and the migration rate was calculated according to the published equation (16).

Transwell migration assay

The cells were seeded in 24-well plates (80,000 cells/well) and diluted using a medium with 30% FBS (100 μ L), while a medium with 30% FBS (600 μ L) was added to the basolateral chamber. Subsequently, the chambers containing cells were transferred to the basolateral chamber and incubated for 24 h. The non-migrated cells were swabbed,

and a 4% paraformaldehyde and Giemsa dye were then added to fix and stain the cells, respectively. A microscope was used to count the cells at 100× magnification.

Xenograft tumor model

A protocol was prepared before the study without registration. A total of 20 4-week-old (weight about 20 g) female Balb/c nude mice were obtained from Shanghai Lingchang Biology (China). The mice were randomly divided into short hairpin (sh)Ctrl and sh*XTP1* groups via random number table method, with 10 mice in each group. Next, the mice were subcutaneously injected with transfected SGC-7901 cells (4×10^6) at the right forelimb. Tumor data collection began after 10 days. Bioluminescence imaging was performed before the mice were sacrificed, and the mice were sacrificed 3 weeks later. Then, the tumor volumes and weights were measured. Hematoxylin and eosin (HE) staining and IHC assays were further performed for the subcutaneous tumor tissues. Animal experiments were performed under a project license (No. XJTULAC2021-1341) granted by the Institutional Animal Care Committee of the Animal Experimental Center of Xi'an Jiaotong University, in compliance with the institutional guidelines for the care and use of animals.

Human GeneChip assay

The Human GeneChip assay was performed with the 3' IVT Plus Kit (Affymetrix, USA). The double-stranded cDNA of the target gene was transcribed to synthesize complementary RNA (cRNA). The cRNA was then purified, quantified, and labeled. The Pre-Hybridization Mix was added and reacted with the GeneChip. Next, the Hybridization Master Mix was mixed with the labeled cRNA, and the mixture was added and reacted with the GeneChip. A GeneChip Scanner and software were used to scan and analyze the GeneChip, respectively. The raw data were filtered and standardized for further bioinformatics analysis, which was performed using Ingenuity Pathway Analysis (IPA) software.

Statistical analysis

GraphPad Prism 8.3.0 was used to analyze the data. The data were expressed as the mean \pm standard error of the mean. *T*-tests, one-way analysis of variance (ANOVA), and two-way repeated-measures ANOVA were used to compare




Figure 1 *XTP1* is upregulated in GC tumor tissues and cell lines. (A) Representative images of *XTP1* staining in the IHC assay. (B) Quantitative analysis of the IHC assay. (C) Detection of *XTP1* expression via GEPIA database analysis. (D) RT-qPCR. *, $P < 0.05$; ***, $P < 0.001$. TPM, transcripts per million; GC, gastric cancer; IHC, immunohistochemistry; RT-qPCR, reverse transcription quantitative polymerase chain reaction.

the differences. A P value < 0.05 indicated that there was a statistically significant difference between the two groups.

Results

XTP1 was overexpressed in GC tissues

To investigate the effects of *XTP1* on GC, we evaluated the *XTP1* expression level in tumor tissues and paracarcinoma tissues of GC patients by IHC. According to the IHC staining results, the *XTP1* protein was significantly overexpressed in tumor tissues compared with adjacent normal tissues (Figure 1A,1B). Furthermore, Spearman rank correlation analysis showed that the expression of *XTP1* was obviously related to the pathological grade and negatively related to patient age (Table 1). The GEPIA database analysis also suggested that *XTP1* was overexpressed in the tumor tissues of GC patients (Figure 1C). In addition, RT-qPCR showed that *XTP1* was highly expressed in GC cell lines, especially BGC-823 and SGC-7901 (Figure 1D). All of the above results indicated that *XTP1* was overexpressed in GC tumor tissues.

XTP1 depletion suppressed GC development and progression *in vitro*

To further explore the role of *XTP1* in GC development, a lentivirus containing shRNA against *XTP1* was constructed and transfected into the BGC-823 and SGC-7901 cell lines

to downregulate the expression of *XTP1*. RT-qPCR and Western blotting showed that the expression of *XTP1* was inhibited after transfection (Figure 2A,2B). Also, MTT and cell cycle assays showed that *XTP1* depletion restrained the proliferation of GC cells (Figure 2C,2D). Subsequently, the effect of *XTP1* knockdown on the apoptosis of GC cells was investigated by flow cytometry and the human apoptosis antibody array. The apoptosis of GC cell lines was significantly promoted (Figure 2E,2F). Additionally, the expression levels of proteins related to cell apoptosis [including B-cell CLL/lymphoma 2 (*Bcl-2*), BCL2-like 2 (*Bcl-w*), *CD40*, *clAP-2*, heat shock protein (*HSP*)27, *HSP60*, *HSP70*, insulin-like growth factors (*IGF*)-I, *IGF-II*, *Livin*, *Survivin*, and soluble tumor necrosis factor receptor 1 (*sTNF-R1*)] were reduced (Figure 2G) when *XTP1* was downregulated. Furthermore, inhibition of the migratory ability was observed in transfected GC cells (Figure 2H,2I). Taken together, these findings indicated that the downregulation of *XTP1* significantly inhibited the proliferation and migration, and promoted the apoptosis of GC cells.

XTP1 depletion inhibited GC growth *in vivo*

Given the effects of *XTP1* knockdown on GC cells *in vitro*, we further evaluated its role in the growth of GC *in vivo*. The tumor volumes and weights were significantly decreased after *XTP1* depletion (Figure 3A-3C). *In vivo* imaging also showed an obvious reduction in the total

Table 1 Relationship between *XTP1* expression and the tumor characteristics of patients with GC

Characteristic	Number	<i>XTP1</i> expression		P value
		Low	High	
Age (years)				0.008
≤56	99	52	47	
>56	97	69	28	
Sex				0.671
Male	135	82	53	
Female	61	39	22	
Pathological grade				0.000
I/II	69	60	9	
III	106	42	64	
NA		21		
T stage				0.972
T1	4	3	1	
T2	25	13	12	
T3	116	65	51	
T4	11	6	5	
NA		40		
Lymph node metastasis				0.125
N0	104	63	41	
N1	34	14	20	
N2	12	8	4	
N3	6	2	4	
NA		40		
Stage				0.076
I	24	15	9	
II	79	48	31	
III	39	18	21	
IV	14	6	8	
NA		40		
Total	196	121	75	–

GC, gastric cancer; NA, not applicable.

fluorescence intensity after *XTP1* depletion (Figure 3D). Notably, we performed HE staining and IHC assays to evaluate the *Ki-67* expression in the mice tumor tissues. A decrease in the *Ki-67* expression level was observed in mice that were subcutaneously injected with *XTP1*-depleted cells (Figure 3E,3F). Collectively, the knockdown of *XTP1* obviously restrained the growth of GC *in vivo*.

XTP1* overexpression facilitated GC development and progression *in vitro

From the above experiments, we found that *XTP1* depletion inhibited GC growth and development. However, whether the overexpression of *XTP1* could also impact GC development was unclear. Thus, we constructed lentivirus and transfected SGC-7901 cells to upregulate *XTP1* expression. The results of RT-qPCR and Western blotting showed that *XTP1* was overexpressed following transfection (Figure 4A,4B). The Celigo cell counting and colony formation assays suggested that *XTP1* overexpression could promote GC cell proliferation (Figure 4C,4D). In addition, flow cytometry indicated that *XTP1* overexpression was inhibited in SGC-7901 cells (Figure 4E). Additionally, the Transwell migration assays and scratch wound-healing assays showed that *XTP1* upregulation promoted the migration of SGC-7901 cells (Figure 4F,4G). Taken together, the above findings suggested that *XTP1* overexpression significantly facilitates the growth of GC cells and suppresses GC cell apoptosis.

Identification of downstream molecules of XTP1 in GC cells

To elucidate the mechanism underlying the effects of *XTP1* on GC cells, we conducted a human GeneChip assay and bioinformatics analysis. Our GeneChip assay identified 642 differentially expressed genes (DEGs) in the SGC-7901 cells with versus without *XTP1* depletion (Figure 5A-5C). We also identified 407 genes that were upregulated and 235 genes that were downregulated after *XTP1* knockdown by hierarchical clustering of the DEGs (Figure 5C). Further IPA highlighted the enrichment of 642 DEGs related to cell death and survival (Figure 5D), as well as the inhibition




Figure 2 *XTP1* depletion suppressed the proliferation and migration of GC cells, while GC cell apoptosis was induced. (A) RT-qPCR. (B) Western blotting. (C) MTT assay. (D) Cell cycle analysis. (E) Representative images of the cell apoptosis analysis. (F) Quantitative analysis of cell apoptosis. (G) Human apoptosis antibody array. (H) Transwell migration assay. (I) Scratch wound-healing assay. The shCtrl group illustrates GC cells that were transfected with lentivirus containing empty plasmid. The sh*XTP1* group shows GC cells transfected with lentivirus to silence *XTP1*. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$. Ctrl, control; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; GC, gastric cancer; MTT, methylthiazolyldiphenyl-tetrazolium bromide; OD, optical density; RT-qPCR, reverse transcription quantitative polymerase chain reaction; sh, short hairpin.




Figure 3 *XTP1* Knockdown inhibited the growth of GC *in vivo*. (A,B) Tumor volume. (C) Tumor weight. (D) Detection of total fluorescence expression by *in vivo* imaging. (E) Detection of Ki-67 by HE staining. (F) Detection of Ki-67 by IHC analysis. The shCtrl group shows GC cells that were transfected with lentivirus containing empty plasmid. The shXTP1 group illustrates SGC-7901 cells that were transfected with lentivirus to silence *XTP1*. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$. Ctrl, control; GC, gastric cancer; HE, hematoxylin and eosin; IHC, immunohistochemistry; sh, short hairpin.

of signaling pathways, including relaxin signaling, small cell lung cancer signaling, and Janus kinase (*JAK*)/signal transducer and activator of transcription (*STAT*) signaling (Figure 5E).

Moreover, the gene interaction network based on IPA showed that *XTP1* could indirectly impact the downstream molecules involved in relaxin signaling, small cell lung cancer signaling, and *JAK/STAT* signaling, including *AKT2*, *BCL2*-like 1 (*BCL2L1*), caspase 9 (*CASP9*), *CDK6*, cyclin-dependent kinase inhibitor 1B (*CDKN1B*), cyclin-dependent kinase inhibitor 2B (*CDKN2B*), insulin receptor substrate 1 (*IRS1*), Jun proto-oncogene (*JUN*), mitogen-activated protein kinase 1 (*MAPK1*), muscle RAS oncogene homolog (*MRAS*), and so on (Figure 5F). These molecules

were selected for further characterization. RT-qPCR showed that *XTP1* knockdown induced the upregulation of seven genes [*CASP9*, thyroid hormone receptor interactor 13 (*TRIP13*), *CDKN1B*, *RHO*, mucin 1 (*MUC1*), bone morphogenetic protein 2 (*BMP2*), and ribosomal protein S6 kinase (*RPS6KB1*)] and the downregulation of eight genes [*CDK6*, *IRS1*, *JUN*, methionyl-tRNA synthetase (*MARS*), serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 2 (*SERPINE2*), adhesion molecule with Ig like domain 2 (*AMGO2*), *CD44*, and plasminogen activator, urokinase (*PLAU*)] (Figure 5G).

Previous studies have suggested that *CD44* is associated with the tumorigenicity, invasion, and lymph node metastasis of cancer cells (17,18), while *CDK6* and *RHO*




Figure 4 *XTP1* overexpression facilitated the proliferation and migration of GC, and inhibited GC cell apoptosis. (A) RT-qPCR. (B) Western blotting. (C) Celigo cell counting assay. (D) Colony formation assay (crystal violet staining, 1 \times). (E) Cell apoptosis analysis. (F) Scratch wound-healing assay (the cells were transfected with lentivirus with enhanced green fluorescent protein). (G) Transwell migration assay (crystal violet staining). The Ctrl group shows SGC-7901 cells transfected with lentivirus containing empty plasmid. The *XTP1* group illustrates SGC-7901 cells transfected with lentivirus to overexpress *XTP1*. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$. Ctrl, control; GC, gastric cancer; PI, propidium iodide; RT-qPCR, reverse transcription quantitative polymerase chain reaction.




Figure 5 Identification of downstream molecules of *XTP1* in SGC-7901 cells using the human GeneChip assay combined with bioinformatics analysis. (A,B) Pearson correlation (A) combined with principal component analysis (B) showed that the data from the GeneChip assay were consistent with the criteria of continuous analysis. (C) Hierarchical clustering of the DEGs showed 407 upregulated genes and 235 downregulated genes after *XTP1* depletion. (D,E) IPA analysis showed that the DEGs were enriched in pathways related to cell death and survival (D) as well as the inhibition of relaxin signaling, small cell lung cancer signaling, and *JAK/STAT* signaling (E). (F) Gene interaction network analysis showed that *XTP1* could indirectly impact the downstream molecules in relaxin signaling, small cell lung cancer signaling, and *JAK/STAT* signaling. (G) RT-qPCR. (H) Western blot analysis. The shCtrl group illustrates SGC-7901 cells that were transfected with lentivirus containing empty plasmid. SGC-7901 cells in the sh*XTP1* group were transfected with lentivirus to silence *XTP1*. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$. sh, short hairpin; Ctrl, control; PC, principal component; var., variable; GC, gastric cancer; DEGs, differentially expressed genes; RT-qPCR, reverse transcription quantitative polymerase chain reaction.

are associated with the cell cycle and cell migration, respectively (19-21). Thus, we conducted a Western blot analysis to confirm the expressions of *CD44*, *CDK6*, and *RHOA*. The results showed that the knockdown of *XTP1* induced *RHOA* upregulation and the downregulation of *CDK6* and *CD44* (Figure 5H). In summary, *XTP1* might affect the biological functions of GC cells via *CDK6*, *CD44*, and *RHOA*.

Knockdown of CDK6 inhibited the growth of GC cells

CDK6 inhibitors have been used in the development of antitumor drugs (20,22). Therefore, we selected *CDK6* for further investigation. First, we confirmed the expression level of *CDK6* in GCs and found that *CDK6* was overexpressed in the GC cell lines (Figure 6A) and tumor tissues (Figure 6B) by RT-qPCR and IHC analysis, respectively. Next, we constructed lentiviruses containing shRNA targeting *CDK6* and transfected SGC-7901 cells. *CDK6* expression was significantly suppressed by lentivirus containing shRNA against *CDK6* (Figure 6C,6D). Proliferation assays illustrated the inhibitory effect of *CDK6* depletion on GC cell growth (Figure 6E,6F). The promoting effect of *CDK6* knockdown on GC cell apoptosis was also observed (Figure 6G). In addition, the migration of GC cells was evaluated by Transwell migration and scratch wound-healing assays. The results indicated that *CDK6* knockdown suppressed the migration of GC cells (Figure 6H,6I). Together, the above results highlighted the critical role of *CDK6* in GC.

XTP1 depletion restrained GC cell growth and development by inhibiting CDK6

To verify whether *XTP1* facilitates the development of GC by regulating *CDK6*, we cotransfected SGC-7901 cells with lentiviruses for overexpressing *XTP1* and silencing *CDK6*. RT-qPCR and Western blot analysis showed that *XTP1* was overexpressed, while *CDK6* was downregulated (Figure 7A-7C). We further evaluated GC cell proliferation, apoptosis, and migration. *CDK6* depletion completely blocked the *XTP1* overexpression-induced enhancement of SGC-7901 cell proliferation (Figure 7D,7E) and migration (Figure 7F,7G). In addition, flow cytometry suggested that the reduction in the apoptosis of GC cells induced by *XTP1* overexpression was alleviated by *CDK6* knockdown (Figure 7H). Taken together, these findings indicated that *CDK6* is a downstream molecule of *XTP1*. Therefore,

XTP1 may facilitate GC cell growth and development by activating *CDK6*.

Discussion

In this study, the role of *XTP1* in the proliferation, apoptosis, and migration of GC cells was identified by depleting or overexpressing *XTP1*, and the potential molecular mechanism was explored using a human GeneChip assay combined with bioinformatics analysis.

XTP1 was upregulated in GC cells and tumor tissues. Further investigation revealed a positive relationship between high *XTP1* expression levels and the malignant degree of GC. Moreover, *XTP1* depletion suppressed the growth and migration of GC cells, while GC cell apoptosis was promoted and the expression of apoptosis-related proteins was inhibited by *XTP1* depletion. These results revealed the important regulatory effects of *XTP1* on GC development. To further verify the effects of *XTP1* on GC cell growth, we upregulated *XTP1* and found that overexpression could obviously increase the proliferative and migratory potential of GC cells and inhibit GC cell apoptosis. The above results comprehensively confirmed that *XTP1* is a potent tumor promoter in GC.

XTP1 was previously recognized as a tumor promoter of bladder cancer by targeting *SHC1* (7). Later, Tao *et al.* found that *XTP1* could activate the *NF-κB* signaling pathway by targeting *TRAF2*, thereby promoting the development of bladder cancer (8). Similarly, *XTP1* was related to cell proliferation and epithelial-mesenchymal transition in prostate cancer via *Rac1-PAK1* signaling (9). In addition, *XTP1* was reported to activate *Wnt/β-catenin* signaling to enhance the migration and invasion of non-small cell lung cancer (6). These previous studies indicated that *XTP1* plays a role in tumorigenesis as a tumor promoter by targeting downstream molecules. In our study, we conducted a human GeneChip assay combined with bioinformatics analysis to identify the possible downstream molecules of *XTP1* in GC and hypothesized that *CDK6* is a potential downstream molecule of *XTP1*. Interestingly, through RT-qPCR and Western blot analysis, we observed the suppression of *CDK6* expression induced by *XTP1* knockdown. Next, we detected whether *CDK6* is involved in GC cell development. We used a lentivirus to silence *CDK6* and evaluated the impact of *CDK6* knockdown on GC cells. We observed that *CDK6* silencing obviously restrained the proliferation and migration, and facilitated the apoptosis of GC cells, indicating that *CDK6* affects the




Figure 6 *CDK6* silencing inhibited the proliferation and migration and promoted the apoptosis of GC cells. (A) RT-qPCR of *CDK6* expression in SGC-7901 cells. (B) Detection of *CDK6* by IHC assay. SGC-7901 cells were transfected with lentivirus containing either *CDK6*-silencing (shCtrl group) or empty plasmids (shCDK6 group). (C) RT-qPCR of *CDK6* expression in SGC-7901 cells after *CDK6* knockdown. (D) Western blotting. (E) Celigo cell counting assay. (F) Colony formation assay (crystal violet staining, 1 \times). (G) Cell apoptosis analysis. (H) Scratch wound-healing assay (the cells were transfected with lentivirus with enhanced green fluorescent protein). (I) Transwell migration assay (crystal violet staining). **, $P < 0.01$; ***, $P < 0.001$. sh, short hairpin; Ctrl, control; PI, propidium iodide; GC, gastric cancer; IHC, immunohistochemistry; RT-qPCR, reverse transcription quantitative polymerase chain reaction.




Figure 7 *CDK6* knockdown attenuated the promoting effect on GC cells growth and development caused by *XTP1* overexpression. (A,B) RT-qPCR. (C) Western blotting. (D) Celigo cell counting assay. (E) Colony formation assay (crystal violet staining, 1×). (F) Scratch wound-healing assay (the cells were transfected with lentivirus with enhanced green fluorescent protein). (G) Transwell migration assay (crystal violet staining). The Ctrl + shCtrl group represents SGC-7901 cells that were transfected with lentivirus containing empty plasmids. (H) Cell apoptosis analysis. The *XTP1* + *ShCDK6* group shows SGC-7901 cells cotransfected with lentiviruses for overexpressing *XTP1* and silencing *CDK6*. *, $P < 0.05$; **, $P < 0.01$; ***, $P < 0.001$. sh, short hairpin; Ctrl, control; PI, propidium iodide; GC, gastric cancer; RT-qPCR, reverse transcription quantitative polymerase chain reaction.

growth of GC cells. Thus, we believe that both *XTP1* and *CDK6* participate in GC tumorigenesis.

CDK6 is a member of the cyclin-dependent kinase family, which can combine with cyclins to form heterodimers and facilitate cell cycle progression (19,23). In the G1/S phase, *CDK6* can combine with cyclin D and promote the phosphorylation of the tumor suppressor Rb, thereby inducing the release of E2F transcription factors from Rb-mediated inhibition. Furthermore, the activation of E2F-dependent genes accelerates the progression of the cell cycle from the G1 to the S phase and DNA synthesis (19). Although *CDK6* is described as a critical regulator in cell cycle progression, the latest studies have confirmed that it also plays a role in hematopoiesis (24), T-cell development (25), and immune responses (26). Moreover, the phenomenon of *CDK6* overexpression has been confirmed in several malignancies, including acute myeloid leukemia (27), breast cancer (28), and melanoma (29). Our study also confirmed the overexpression of *CDK6* in GC cells and its important role in GC development. The critical role of *CDK6* in promoting tumor occurrence and development makes it an attractive target for drug inhibition (30). In this study, *XTP1* knockdown resulted in the downregulation of *CDK6*, indicating that *XTP1* might modulate GC development by regulating *CDK6* expression. When *XTP1* was overexpressed and *CDK6* was depleted simultaneously, facilitation of the growth and migration of GC cells induced by *XTP1* was attenuated via *CDK6* knockdown. *CDK6* knockdown also eliminated the inhibitory effect of *XTP1* depletion on GC cells. These results revealed that *XTP1* knockdown regulated GC progression by inhibiting *CDK6* expression. However, whether *XTP1* could bind with *CDK6* was not verified in this study. Thus, in the next step, we will confirm the interaction of *XTP1* and *CDK6*.

Conclusions

In summary, our findings indicate that *XTP1* might be a tumor promoter facilitating GC progression, and *XTP1* is overexpressed in GC tumor tissues and relevant to the malignant degree of GC. Both *XTP1* and *CDK6* play critical roles in GC cell proliferation, migration, and apoptosis. Notably, *XTP1* can regulate the growth of GC cells by acting on *CDK6*. In conclusion, our study may provide a new understanding of the pathogenesis and mechanism of GC. The *XTP1-CDK6* axis could be used in further studies on GC treatment.

Acknowledgments

Funding: This work was supported by the Natural Science Foundation of Shaanxi Province (No. 2021JM-263).

Footnote

Reporting Checklist: The authors have completed the ARRIVE and MDAR reporting checklists. Available at <https://atm.amegroups.com/article/view/10.21037/atm-22-5933/rc>

Data Sharing Statement: Available at <https://atm.amegroups.com/article/view/10.21037/atm-22-5933/dss>

Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at <https://atm.amegroups.com/article/view/10.21037/atm-22-5933/coif>). The authors have no conflicts of interest to declare.

Ethical Statement: The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved. The study was conducted in accordance with the Declaration of Helsinki (as revised in 2013). The study was approved by the clinical ethics committee of the First Affiliated Hospital of Xi'an Jiaotong University (No. XJTU1AF2020LSK-103). The study was a retrospective study, and written informed consent for participation was not required for this study in accordance with the national legislation and the institutional requirements, so it was waived by the Ethics Committee of the First Affiliated Hospital of Xi'an Jiaotong University. Animal experiments were performed under a project license (No. XJTULAC2021-1341) granted by the Institutional Animal Care Committee of the Animal Experimental Center of Xi'an Jiaotong University, in compliance with the institutional guidelines for the care and use of animals.

Open Access Statement: This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license).

See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

References

- Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin* 2021;71:209-49.
- Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. *CA Cancer J Clin* 2016;66:115-32.
- Mousa H, Yuan M, Zhang X, et al. MicroRNA-4316 inhibits gastric cancer proliferation and migration via directly targeting VEGF-A. *Cancer Cell Int* 2020;20:62.
- Figeac N, Pruller J, Hofer I, et al. DEPDC1B is a key regulator of myoblast proliferation in mouse and man. *Cell Prolif* 2020;53:e12717.
- Zhang L, Du Y, Xu S, et al. DEPDC1, negatively regulated by miR-26b, facilitates cell proliferation via the up-regulation of FOXM1 expression in TNBC. *Cancer Lett* 2019;442:242-51.
- Yang Y, Liu L, Cai J, et al. DEPDC1B enhances migration and invasion of non-small cell lung cancer cells via activating Wnt/ β -catenin signaling. *Biochem Biophys Res Commun* 2014;450:899-905.
- Lai CH, Xu K, Zhou J, et al. DEPDC1B is a tumor promoter in development of bladder cancer through targeting SHC1. *Cell Death Dis* 2020;11:986.
- Tao H, Liao Y, Yan Y, et al. BRCC3 Promotes Tumorigenesis of Bladder Cancer by Activating the NF- κ B Signaling Pathway Through Targeting TRAF2. *Front Cell Dev Biol* 2021;9:720349.
- Li Z, Wang Q, Peng S, et al. The metastatic promoter DEPDC1B induces epithelial-mesenchymal transition and promotes prostate cancer cell proliferation via Rac1-PAK1 signaling. *Clin Transl Med* 2020;10:e191.
- Xu Y, Sun W, Zheng B, et al. DEPDC1B knockdown inhibits the development of malignant melanoma through suppressing cell proliferation and inducing cell apoptosis. *Exp Cell Res* 2019;379:48-54.
- Dang XW, Pan Q, Lin ZH, et al. Overexpressed DEPDC1B contributes to the progression of hepatocellular carcinoma by CDK1. *Aging (Albany NY)* 2021;13:20094-115.
- Zhang S, Shi W, Hu W, et al. DEP Domain-Containing Protein 1B (DEPDC1B) Promotes Migration and Invasion in Pancreatic Cancer Through the Rac1/PAK1-LIMK1-Cofilin1 Signaling Pathway. *Onco Targets Ther* 2020;13:1481-96.
- Liu X, Li T, Huang X, et al. DEPDC1B promotes migration and invasion in pancreatic ductal adenocarcinoma by activating the Akt/GSK3 β /Snail pathway. *Oncol Lett* 2020;20:146.
- Wang L, Tang L, Xu R, et al. DEPDC1B regulates the progression of human chordoma through UBE2T-mediated ubiquitination of BIRC5. *Cell Death Dis* 2021;12:753.
- Su YF, Liang CY, Huang CY, et al. A putative novel protein, DEPDC1B, is overexpressed in oral cancer patients, and enhanced anchorage-independent growth in oral cancer cells that is mediated by Rac1 and ERK. *J Biomed Sci* 2014;21:67.
- Ma R, Zhu K, Yuan D, et al. Downregulation of the FBXO43 gene inhibits tumor growth in human breast cancer by limiting its interaction with PCNA. *J Transl Med* 2021;19:425.
- Chen C, Zhao S, Karnad A, et al. The biology and role of CD44 in cancer progression: therapeutic implications. *J Hematol Oncol* 2018;11:64.
- Naor D, Nedvetzki S, Golan I, et al. CD44 in cancer. *Crit Rev Clin Lab Sci* 2002;39:527-79.
- Nebenfuhr S, Kollmann K, Sexl V. The role of CDK6 in cancer. *Int J Cancer* 2020;147:2988-95.
- Tadesse S, Yu M, Kumarasiri M, et al. Targeting CDK6 in cancer: State of the art and new insights. *Cell Cycle* 2015;14:3220-30.
- Zhang JS, Koenig A, Young C, et al. GRB2 couples RhoU to epidermal growth factor receptor signaling and cell migration. *Mol Biol Cell* 2011;22:2119-30.
- Wang H, Nicolay BN, Chick JM, et al. The metabolic function of cyclin D3-CDK6 kinase in cancer cell survival. *Nature* 2017;546:426-30.
- Tigan AS, Bellutti F, Kollmann K, et al. CDK6—a review of the past and a glimpse into the future: from cell-cycle control to transcriptional regulation. *Oncogene* 2016;35:3083-91.
- Laurenti E, Frelin C, Xie S, et al. CDK6 levels regulate quiescence exit in human hematopoietic stem cells. *Cell Stem Cell* 2015;16:302-13.
- Hu MG, Deshpande A, Enos M, et al. A requirement for cyclin-dependent kinase 6 in thymocyte development and tumorigenesis. *Cancer Res* 2009;69:810-8.
- Goel S, DeCristo MJ, Watt AC, et al. CDK4/6 inhibition triggers anti-tumour immunity. *Nature* 2017;548:471-5.
- Schmoellerl J, Barbosa IAM, Eder T, et al. CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. *Blood* 2020;136:387-400.

28. Goel S, Wang Q, Watt AC, et al. Overcoming Therapeutic Resistance in HER2-Positive Breast Cancers with CDK4/6 Inhibitors. *Cancer Cell* 2016;29:255-69.
29. Read J, Wadt KA, Hayward NK. Melanoma genetics. *J Med Genet* 2016;53:1-14.
30. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. *Nat Rev Cancer* 2009;9:153-66.

Cite this article as: Li K, Ma R, Meng L, Wang Q, Cao J, Yuan D, Sun T, Kang L, Hao N, Wang H, Zhu K. *XTP1* facilitates the growth and development of gastric cancer by activating *CDK6*. *Ann Transl Med* 2023;11(2):97. doi: 10.21037/atm-22-5933